Skip to content

A predictive nomogram based on sub-anesthetic esketamine and clinical variables for estimating the risk of postoperative depression following laparoendoscopic single-site hysterectomy

Kun Shao, Weili Han, Xu Cao, Yang Hai, Xiangkai Fan, Jiajie Li

Frontiers in Medicine November 10, 2026 DOI: 10.3389/fmed.2026.1943794 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Retrospective observational cohort with prediction model development and internal validation Peer reviewed
Sample size 326
Population Patients who underwent laparoendoscopic single-site (LESS) hysterectomy
Intervention Esketamine
Duration Postoperative day 7 assessment
Measures 17-item Hamilton Depression Rating Scale (HAMD-17), visual analogue scale (VAS)
Topics Depression Esketamine
Key findings Postoperative depression occurred in 23.62% (77/326) of patients. The nomogram showed acceptable discrimination (AUC 0.884 in training, 0.772 in internal validation) but poor calibration in internal validation (slope 0.467, intercept −0.925, Brier score 0.167), systematically overestimating risk and indicating overfitting. The authors conclude it should be regarded as an exploratory risk-stratification tool requiring external validation and recalibration before clinical use.

Abstract

Objective: To construct a nomogram combining sub-anesthetic esketamine administration with perioperative clinical characteristics for predicting postoperative depression in patients undergoing laparoendoscopic single-site (LESS) hysterectomy.

Methods: Clinical records from 326 patients who underwent LESS hysterectomy were retrospectively reviewed. Participants were randomly assigned to training ( n =228) and internal validation ( n = 98) cohorts at a 7:3 ratio. Using the 17-item Hamilton Depression Rating Scale (HAMD-17) on postoperative day 7, patients in the training cohort were classified into depression (HAMD-17 ≥ 7) and non-depression (HAMD-17 < 7) groups. A nomogram was established, and its discrimination, calibration, and clinical utility were evaluated using receiver operating characteristic (ROC) analysis, calibration curves, and decision curve analysis (DCA).

Results: Postoperative depression occurred in 23.62% (77/326) of patients: 22.81% (52/228) and 25.51% (25/98) in the training and internal validation cohorts, respectively. Multivariable logistic regression identified the 12-hour postoperative visual analogue scale (VAS) score (OR = 3.165, 95% CI: 1.223–8.192), increasing age (OR = 1.126, 95% CI: 1.053–1.205), and prolonged operative duration (OR = 1.046, 95% CI: 1.014–1.078) as independent risk factors (all P < 0.05), whereas higher preoperative serum albumin (OR = 0.785, 95% CI: 0.684–0.900), single-dose esketamine (OR = 0.290, 95% CI: 0.118–0.714), and continuous-dose esketamine (OR = 0.306, 95% CI: 0.116–0.803) were protective (all P < 0.05). The nomogram achieved areas under the ROC curve of 0.884 (95% CI: 0.829–0.942) and 0.772 (95% CI: 0.637–0.906) in the training and validation cohorts. Calibration was good in the training cohort (slope = 1.000, intercept = 0.000) but was poor in the internal validation cohort (slope = 0.467, 95% CI: 0.215–0.719; intercept = −0.925, 95% CI: −1.386 to −0.464; Brier score = 0.167), indicating systematic overestimation of predicted risk and overfitting. DCA indicated favorable clinical utility. SHapley Additive exPlanations ranked predictors as operative time, age, preoperative albumin, esketamine administration, and 12-hour VAS score.

Conclusion: The nomogram demonstrated acceptable discrimination but poor calibration in internal validation, systematically overestimating postoperative depression risk; it should be regarded as an exploratory tool for postoperative risk stratification and requires external validation and recalibration before any clinical application. Chinese Clinical Trial Registry Number ChiCTR2500103453

Comparable studies

Other observational and cohort studies on esketamine for depression, most cited first.

Study Year Design Participants
Treating bipolar depression with esketamine: Safety and effectiveness data from a naturalistic multicentric study on esketamine in bipolar versus unipolar treatment‐resistant depression Patients with treatment-resistant bipolar depression (B-TRD) and unipolar... 2023 Observational cohort n = 70
Comparative Effectiveness of Intravenous Ketamine and Intranasal Esketamine in Clinical Practice Among Patients With Treatment-Refractory Depression: An Observational Study. Adults with treatment-resistant depression 2023 Observational study n = 62
Predicting outcome with Intranasal Esketamine treatment: A machine-learning, three-month study in Treatment-Resistant Depression (ESK-LEARNING) Treatment-resistant depression patients 2023 Retrospective, multicentric, real-world study n = 149
Esketamine in treatment-resistant depression patients comorbid with substance-use disorder: A viewpoint on its safety and effectiveness in a subsample of patients from the REAL-ESK study Patients with treatment-resistant depression and a substance use disorder 2023 Observational, retrospective, multicentre study n = 26
Rapid infusion of esketamine for unipolar and bipolar depression: a retrospective chart review Patients with treatment-resistant depression and bipolar depression meeting DSM-IV-TR... 2017 Retrospective observational study n = 27

Citations in the library

Explore topics

By condition and practice